Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response

Figure 9

Association of risk signature with anti-PD-1 immunotherapy treatment response of GSE78220 cohort. (a) Kaplan-Meier analysis of OS of anti-PD-1 immunotherapy-treated patients with different risk scores. (b) Difference of risk score among complete anti-PD-1 immunotherapy response, partial anti-PD-1 immunotherapy response, and no anti-PD-1 immunotherapy response. (c) Difference of risk score between alive patient with anti-PD-1 immunotherapy and dead patients with anti-PD-1 immunotherapy. (d) AUC of risk signature in predicting1-year, 1.5-year, and 2-year OS in patients with anti-PD-1 immunotherapy response.

(a)

(b)

(c)

(d)